نتایج جستجو برای: nsclc

تعداد نتایج: 17801  

ژورنال: :یافته های نوین در علوم زیستی 0
پروین پیشوا parvin pishva kharazmi universityدانشگاه خوارزمی محمد طهماسب mohammad tahmaseb kharazmi universityدانشگه خوارزمی عباس قادری abbass ghaderi fars medical science universityدانشگاه علوم پزشکی فارس

سرطان ریه شایع­ ترین عامل مرگ­ و میر ناشی از سرطان در سطح جهان است و محاسبه شده حدود 1.4 میلیون مرگ در هر سال با این سرطان مرتبط است. سرطان ریه پنجمین سرطان شایع در ایران، با نرخ شیوع 2/9-7/4 در هر 100 هزار نفر است. با وجود شیوع کم، بقا آن نیز محدود است. کشف نشانگرهای بیولوژیکی و کاربرد آنها در رابطه با تشخیص سرطان می­تواند منجر به تشخیص زودهنگام و در نتیجه افزایش میزان بقا بیماران شود. در این ...

Journal: :international journal of hematology-oncology and stem cell research 0
m hoseinzadeh mollayosefy department of hematology and oncology, shariati hospital, school of medicine, tehran university of medical science, tehran, iran m iravani department of hematology and oncology, shariati hospital, school of medicine, tehran university of medical science, tehran, iran a ghavamzadeh department of hematology and oncology, shariati hospital, school of medicine, tehran university of medical science, tehran, iran gh toogheh deparment of hematology and oncology, emam khomeini (rah) hospital, school of medicine, tehran university of medical science, tehran, iran k alimoghaddam department of hematology and oncology, shariati hospital, school of medicine, tehran university of medical science, tehran, iran

background: cisplatin-based chemotherapy is the standard treatment for advanced non-small cell lung cancer (nsclc). many novel drugs, including gemcitabine, vinorelbine, paclitaxel and docetaxel have been used in combination with cisplatin in this setting. of these drugs, gemcitabine is reported to have a high response rate and acceptable toxicity. the aim of this study was to evaluate the effi...

C. Geng, C. Gong, D. Chen, D. Shu, H. Yu, S. Hang, X. Tang,

Background: Boron neutron capture therapy (BNCT) is a radiotherapy that combines biological targeting and high linear energy transfer. A potential therapeutic approach for non-small cell lung cancer (NSCLC) is considered. However, dose in lung tumor is not homogeneous, and it will reduce the effect of BNCT treatment. In order to improve the dose distribution of BNCT, the multi-field irradiation...

Journal: :iranian journal of radiation research 0
x. tang department of nuclear science and engineering, nanjing university of aeronautics and astronautics, nanjing 210016, china x. tang department of nuclear science and engineering, nanjing university of aeronautics and astronautics, nanjing 210016, china d. shu department of nuclear science and engineering, nanjing university of aeronautics and astronautics, nanjing 210016, china c. geng department of nuclear science and engineering, nanjing university of aeronautics and astronautics, nanjing 210016, china c. gong department of nuclear science and engineering, nanjing university of aeronautics and astronautics, nanjing 210016, china s. hang department of nuclear science and engineering, nanjing university of aeronautics and astronautics, nanjing 210016, china

background: boron neutron capture therapy (bnct) is a radiotherapy that combines biological targeting and high linear energy transfer. a potential therapeutic approach for non-small cell lung cancer (nsclc) is considered. however, dose in lung tumor is not homogeneous, and it will reduce the effect of bnct treatment. in order to improve the dose distribution of bnct, the multi-field irradiation...

Journal: :journal of advanced medical sciences and applied technologies 0
arafat tfayli nk basile cancer institute, american university of beirut medical center, beirut hamid attarian department of hematology-oncology, school of medicine, shahid beheshti university of medical sciences, tehran, iran mojtaba ghadyani department of hematology-oncology, school of medicine, shahid beheshti university of medical sciences, tehran, iran atabak ghotb behphar scientific committee, behphar group, tehran, iran mehrdad mashadian hematology-oncology division, atieh hospital, tehran, iran babak salimi department of hematology-oncology, school of medicine, shahid beheshti university of medical sciences, tehran, iran

given the unmet needs in cancer treatment, extensive research and development has evolved to offer therapies for cancers to extend survival and minimize side effects. immunotherapy, an approach to harness normal immune cells against cancers not only today’s breakthrough but in fact the future of oncology therapeutics. taking into consideration the recent approvals for new lines of therapy inclu...

Journal: :Journal of The National Comprehensive Cancer Network 2021

Updates to the NCCN Guidelines for Non–Small Cell Lung Cancer (NSCLC) 2021 include recommendations biomarker testing in all appropriate patients with newly diagnosed advanced lung cancer, including squamous cell cancer. When a targetable genetic alteration is detected, recommend treatment first-line therapy targeted that alteration. The guidelines contain new information on use of adjuvant osim...

B. Sun, J. Gao, J. He, J. Qiu, J. Yang, L. Qian, L. Yang, L. Zhou, R. Wang, Y. Huang, Y. Zhou, Y.Y. Cui, Y.Y. Zhang, Z.C. Tao,

Previous studies show inconsistent effect estimates for the efficacy of Endostar in patients with advanced non-small cell lung cancer (NSCLC) undergoing chemoradiotherapy. Therefore, this meta-analysis aimed to determine the effectiveness and safety on the basis of data obtained from available randomized controlled trials (RTCs). We find relevant articles reporting the use of Endostar combined ...

طهماسب, محمد, قادری, عباس, پیشوا, پروین,

Lung cancer is the most common cause of death worldwide and result in 1.4 million deaths per year. Lung cancer is the fifth most common cancer in Iran, with rates of 4.7 to 9.2 per 100 thousand populations. Despite the low incidence, survival is not promising. Identification of biological markers and their application in diagnosis of cancer could lead to early diagnosis and therefore longer sur...

Journal: :Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research 1996
M K Ganapathi A K Weizer S Borsellino R M Bukowski R Ganapathi T Rice G Casey K Kawamura

The role of interleukin 6 (IL-6) in regulating the growth of three human non-small cell lung carcinoma (NSCLC) cell lines (NSCLC-3, NSCLC-5, and NSCLC-7, derived from a primary lesion, a brain lesion, and lymph node metastases, respectively) was examined. Although IL-6 alone did not alter the growth of these cells, the addition of soluble IL-6 receptor (sIL-6R) led to the inhibition of prolifer...

C.Y. Kim, D.S. Yang, J.A. Lee, J.H. Kim, N.K. Lee, S. Lee, W.S. Yoon, Y.J. Park,

Background: To determine which radiotherapy parameters are associated with the tumor response of locally advanced non-small cell lung cancer (NSCLC) patients undergoing concurrent chemoradiotherapy. Materials and Methods: Thirty one patients with IIIA/IIIB NSCLC underwent chemoradiotherapy with a median dose of 63 Gy. On our actual treatments, we made radiotherapy planning to cover the planning...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید